vTv Therapeutics Inc. (VTVT) Trading Down 5.7%
vTv Therapeutics Inc. (NASDAQ:VTVT) shares traded down 5.7% on Thursday . The stock traded as low as $5.28 and last traded at $5.33, with a volume of 67,579 shares. The stock had previously closed at $5.65.
VTVT has been the topic of a number of research reports. Zacks Investment Research raised shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 24th. Canaccord Genuity reaffirmed a “buy” rating and issued a $15.00 price target on shares of vTv Therapeutics in a research note on Friday, August 19th.
The firm’s 50-day moving average price is $5.71 and its 200 day moving average price is $5.78. The company’s market cap is $51.65 million.
vTv Therapeutics (NASDAQ:VTVT) last posted its earnings results on Tuesday, August 16th. The company reported ($0.47) EPS for the quarter. On average, equities research analysts expect that vTv Therapeutics Inc. will post ($1.39) EPS for the current year.
In other news, Director Paul G. Savas acquired 6,000 shares of the stock in a transaction dated Friday, May 27th. The stock was bought at an average price of $5.67 per share, with a total value of $34,020.00. Following the completion of the purchase, the director now directly owns 58,781 shares of the company’s stock, valued at approximately $333,288.27. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.